Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OXiGENE has entered into a Committed Equity Financing Facility or CEFF with Kingsbridge Capital, a private investment group, in which Kingsbridge has committed to provide up to $40 million of capital during the next three years through the purchase of newly-issued shares of OXiGENE's common stock.
Subscribe to our email newsletter
Under the terms of the agreement, OXiGENE will determine the exact timing and amount of any CEFF financings, subject to certain conditions. OXiGENE can access up to $40 million from Kingsbridge in exchange for newly-issued shares of OXiGENE’s common stock. Kingsbridge is committed under the CEFF to purchase the lesser of approximately 5.7 million shares of common stock or $40 million of common stock from OXiGENE. The agreement does not prohibit OXiGENE from conducting additional debt or equity financing, other than financings similar to the CEFF.
Jim Murphy, vice president and CFO of OXiGENE, said: “We expect the CEFF to enhance OXiGENE’s financial flexibility as we work to advance our drug development programs and business development initiatives.”